CD3 hyporesponsiveness and in vitro apoptosis are features of T cells from both malignant and nonmalignant secondary lymphoid organs

Journal of Clinical Investigation

Volumn 102, Issue 9, 1998, Pages 1715-1723

  Agrawal, Samir ^a,b   Marquet, Jeanine ^a   Delfau Larue, Marie Hélène ^a   Copie Bergman, Christiane ^a   Jouault, Hélène ^a   Reyes, Felix ^a   Bensussan, Armand ^a   Farcet, Jean Pierre ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b INSERM   (France)

Author keywords

Anergy; Bcl 2; Inflammatory tissue; Non Hodgkin's lymphoma; Tumor infiltrating lymphocytes

Indexed keywords

CD3 ANTIGEN; FAS ANTIGEN; FAS LIGAND; INTERLEUKIN 2; MONOCLONAL ANTIBODY; PROTEIN BCL 2; T LYMPHOCYTE RECEPTOR;

APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CELL CYCLE; CELL SURVIVAL; CHRONIC INFLAMMATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPHENOTYPING; LYMPHOCYTE PROLIFERATION; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE;

EID: 0032213773     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI3784     Document Type: Article

References (71)

1. Cardoso, A.A., J.L. Schultze, V.A. Boussiotis, G.J. Freeman, M.J. Seamon, S. Laszlo, A. Billet, S.E. Sallan, J.G. Grihben, and L.M. Nadler. 1996. Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen. Blood. 88:41-48.
2. Gajewski, T.F., F. Fallarino, C. Uyttenhove, and T. Boon. 1996. Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization. J. Immunol. 156:2909-2917.
3. Gajewski, T.F. 1996. B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro. J. lmmunol. 156:465-472.
4. Hersh, E.M., and B. Drewinko. 1974. Specific inhibition of lymphocyte blastogenic responses to mitogens by a factor produced by cultured human malignant lymphoma cells. Cancer Res. 34:215-220.
5. Roszman, T., L. Elliott, and W. Brooks. 1991. Modulation of T-cell function by gliomas. Immunol. Today. 12:370-374.
6. Miescher, S., T.L. Whiteside, S. Carrel, and V. von Fliedner. 1986. Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes. J. Immunol. 136:1899-1907.
7. Miescher, S., T.L. Whiteside, L. Moretta, and V. von Fliedner. 1987. Clonal and frequency analyses of tumor-infiltrating T lymphocytes from human solid tumors. J Immunol. 138:4004-4011.
8. Miescher, S., M. Stoeck, L. Qiao, C. Barras, L. Barrelet, and V. von Fliedner. 1988. Proliferative and cytolytic potentials of purified human tumor-infiltrating T lymphocytes. Impaired response to mitogen-driven stimulation despite T-cell receptor expression. Int. J. Cancer. 42:659-666.
9. Finke, J.H., A.H. Zea, J. Stanley, D.L. Longo, H. Mizoguchi, R.R. Tubbs, R.H. Wiltrout, J.J. O'Shea, S. Kudoh, E. Klein, et al. 1993. Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma. Cancer Res. 53:5613-5616.
10. Alexander, J.P., S. Kudoh, K.A. Melsop, T.A. Hamilton, M.G. Edinger, R.R. Tubbs, D. Sica, L. Tuason, E. Klein, R.M. Bukowski, et al. 1993. T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors. Cancer Res. 53:1380-1387.
11. Kudoh, S., Q. Wang, O.F. Hidalgo, P. Rayman, R.R. Tubbs, M.G. Edinger, V. Kolenko, J. Panuto, R. Bukowski, and J.H. Finke. 1995. Responses to T cell receptor/CD3 and interleukin-2 receptor stimulation are altered in T cells from B ceil non-Hodgkin's lymphomas. Cancer Immunol. lmmunother. 41: 175-184.
12. Jacob, M.C., M.P. Piccinni, T. Bonnefoix, M.F. Sotto, P. Couderc, J.C. Bensa, and J.J. Sotto. 1990. T lymphocytes from invaded lymph nodes in patients with B-cell-derived non-Hodgkin's lymphoma: reactivity toward the malignant clone. Blood. 75:1154-1162.
13. Boirivant, M., R. Pica, R. DeMaria, R. Testi, F. Pallone, and W. Strober. 1996. Stimulated human lamina propria T cells manifest enhanced Fas-mediated apoptosis. J. Clin. Invest. 98:2616-2622.
14. Maurice, M.M., A.C. Lankester, A.C. Bezemer, M.F. Geensma, P.P. Tak, F.C. Breedveld, R.A. van Lier, and C.L. Verweij. 1997. Defective TCR-mediated signaling in synovial T cells in rheumatoid arthritis. J. Immunol. 159: 2973-2978.
15. Pirzer, U.C., G. Schurmann, S. Post, M. Betzler, and S.C. Meuer. 1990. Differential responsiveness to CD3-Ti vs. CD2-dependent activation of human intestinal T lymphocytes. Eur. J. Immunol. 20:2339-2342.
16. Mizoguchi, H., J.J. O'Shea, D.L. Longo, C.M. Loeffler, D.W. McVicar, and A.C. Ochoa. 1992. Alterations in signal transduction molecules in T lymphocytes from tumor-hearing mice. Science. 258:1795-1798.
17. Franco, J.L., P. Ghosh, R.H. Wiltrout, C.R. Carter, A.H. Zea, N. Momozaki, A.C. Ochoa, D.L. Longo, T.J. Sayers, and K.L. Komschlies. 1995. Partial degradation of T-cell signal transduction molecules by contaminating granulocytes during protein extraction of splenic T cells from tumor-bearing mice. Cancer Res. 55:3840-3846.
18. Li, X., J. Liu, J.K. Park, T.A. Hamilton, P. Rayman, E. Klein, M. Edinger, R. Tubbs, R. Bukowski, and J. Finke. 1994. T cells from renal cell carcinoma patients exhibit an abnormal pattern of kappa B-specific DNA-binding activity: a preliminary report. Cancer Res. 54:5424-5429.
19. Levey, D.L., and P.K. Srivastava. 1996. Alterations in T cells of cancerbearers: whence specificity? Immunol. Today. 17:365-368.
20. Nakagomi, H., M. Petersson, I. Magnusson, C. Juhlin, M. Matsuda, H. Mellstedt, J.L. Taupin, E. Vivier, P. Anderson, and R. Kiessling. 1993. Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Rex. 53:5610-5612.
21. Cardi, G., J.A. Heaney, A.R. Schned, D.M. Phillips, M.T. Branda, and M.S. Ernstoff. 1997. T-cell receptor zeta-chain expression on tumor-infiltrating lymphocytes from renal cell carcinoma. Cancer Res. 57:3517-3519.
22. Wang, Q., J. Stanley, S. Kudoh, J. Myles, V. Kolenko, T. Yi, R. Tubbs, R. Bukowski, and J. Finke. 1995. T cells infiltrating non-Hodgkin's B cell lymphomas show altered tyrosine phosphorylation pattern even though T cell receptor/CD3-associated kinases are present. J. Immunol. 155:1382-1392.
23. Salmon, M., D. Scheel-Toellner, A.P. Huissoon, D. Pilling, N. Shamsadeen, H. Hyde, A.D. D'Angeac, P.A. Bacon, P. Emery, and A.N. Akbar. 1997. Inhibition of T cell apoptosis in the rheumatoid synovium. J. Clin. Invest. 99:439-446.
24. Rieux-Laucat, F., F. Le Deist, C. Hivroz, I.A. Roberts, K.M. Debatin, A. Fischer, and J.P. de Villartay. 1995. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science. 268:1347-1349.
25. Hathcock, K.S., G. Laszlo, C. Pucillo, P. Linsley, and R.J. Hodes. 1994. Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J. Exp. Med. 180:631-640.
26. Boussiotis, V.A., G.J. Freeman, J.G. Gribben, J. Daley, G. Gray, and L.M. Nadler. 1993. Activated human B lymphocytes express three CTLA-4 counterreceptors that costimulate T-cell activation. Proc. Natl. Acad. Sci. USA. 90:11059-11063.
27. Schiavon, V., P. Roth, W.E. Bolton, J.P. Farce t, A. Bensussan, and L. Boumsell. 1996. Lymphocyte subsets in normal individuals: analysis by four color immunofluorescence and flow cytometry on whole blood. Tissue Antigens. 48:312-318.
28. Byrne, J.A., J.L. Butler, and M.D. Cooper. 1988. Differential activation requirements for virgin and memory T cells. J. Immunol. 141:3249-3257.
29. Horgan, K.J., G.A. Van Seventer, Y. Shimizu, and S. Shaw. 1990. Hyporesponsiveness of "naive" (CD45RA+) human T cells to multiple receptor-mediated stimuli but augmentation of responses by co-stimuli. Eur. J. Immunol. 20:1111-1118.
30. Koopman, G., C.P. Reutelingsperger, G.A. Kuijten, R.M. Keehnen, S.T. Pals, and M.H. van Oers. 1994. Annexin V for flow cytometric detection of phosphatidylscrine expression on B ceils undergoing apoptosis. Blood. 84: 1415-1420.
31. Naito, M., K. Nagashima, T. Mashima, and T. Tsuruo. 1997. Phosphatidylserine externalization is a downstream event of interleukin-1β-converting enzyme family protease activation during apoptosis. Blood. 89:2060-2066.
32. Boehme, S.A., and M.J. Lenardo. 1993. Propriocidal apoptosis of mature T lymphocytes occurs at S phase of the cell cycle. Eur. J. Immunol. 23: 1552-1560.
33. Chao, D.T., and S.J. Korsmeyer. 1998. BCL-2 family: regulators of cell death. Annu. Rev. Immunol. 16:395-419.
34. Akbar, A.N., N.J. Borthwick, R.G. Wickremasinghe, P. Panayoitidis, D. Pilling, M. Bofill, S. Krajewski, J.C. Reed, and M. Salmon. 1996. Interleukin-2 receptor common gamma-chain signaling cytokines regulate activated T cell apoptosis in response to growth factor withdrawal: selective induction of antiapoptotic (bcl-2, bcl-xL) but not pro-apoptotic (bax, bcl-xS) gene expression. Eur. J. Immunol. 26:294-299.
35. Cho, E.A., M.P. Riley, A.L. Sillman, and H. Quill. 1993. Altered protein tyrosine phosphorylalion in anergic Th1 cells. J. Immunol. 151:20-28.
36. Correa, M.R., A.C. Ochoa, P. Ghosh, H. Mizoguchi, L. Harvey, and D.L. Longo. 1997. Sequential development of structural and functional alterations in T cells from tumor-bearing mice. J. Immunol. 158:5292-5296.
37. Migita, K., K. Eguchi, Y. Kawabe, T. Tsukada, Y, Ichinose, S. Nagataki, and A. Ochi. 1995. Defective TCR-mediated signaling in anergic T cells. J. Immunol. 155:5083-5087.
38. Loeffler, C.M., M.J. Smyth, D.L. Longo, W.C Kopp, L.K. Harvey, H.R. Tribble, J.E. Tase, W.J. Urba, A.S. Leonard, H.A. Young, et al. 1992. Immunoregulation in cancer-bearing hosts. Down-regulation of gene expression and cytotoxic function in CD8+ T cells. J. Immunol. 149:949-956.
39. Xerri, L., M.P. Mathoulin, F. Birg, R. Bouabdallah, A.M. Stoppa, and J. Hassoun. 1994. Heterogeneity of rearranged T-cell receptor V-alpha and V-beta transcripts in tumor-infiltrating lymphocytes from Hodgkin's disease and non-Hodgkin's lymphoma. Am. J. Clin. Pathol. 101:76-80.
40. Hsu, S.M., J.W. Waldron, Jr., P.L. Hsu, and A.J. Hough, Jr. 1993. Cytokines in malignant lymphomas: review and prospective evaluation. Hum. Pathol. 24:1040-1057.
41. Peuchmaur, M., D. Emilie, M.C. Crevon, N. Brousse, P. Gaulard, M.F. D'Agay, P. Galanaud, and P. Solal-Celigny. 1991. Interleukin-2 and interferon-gamma production in follicular lymphomas. Am. J. Clin. Pathol. 95:55-62.
42. Toellner, K.M., D. Scheel-Toellner, R. Sprenger, M. Duchrow, L.H. Trumper, M. Ernst, H.D. Flad, and J. Gerdes. 1995. The human germinal centre cells, follicular dendritic cells and germinal centre T cells produce B cell-stimulating cytokines. Cytokine. 7:344-354.
43. Voorzanger, N., R. Touitou, E. Garcia, H.J. Delecluse, F. Rousset, I. Joab, M.C. Favrot, and J.Y. Blay. 1996. Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors. Cancer Res. 56:5499-5505.
44. Moore, K.W., A. O'Garra, R. de Waal Malefyt, P. Vieira, and T.R. Mosmann. 1993. Interleukin-10. Annu. Rev. Immunol. 11:165-190.
45. de Waal Malefyt, R., H. Yssel, and J.E. de Vries. 1993. Direct effects of IL-10 on subsets of human CD4+ T cell clones and resting T cells. Specific inhibition of IL-2 production and proliferation. J. Immunol. 150:4754-4765.
46. Del Prete, G., M. De Carli, F. Almerigogna, M.G. Giudizi, R. Biagiotti, and S. Romagnani. 1993. Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J. Immunol. 150:353-360.
47. Taga, K., H. Mostowski, and G. Tosato. 1993. Human interleukin-10 can directly inhibit T-cell growth. Blood. 81:2964-2971.
48. Groux, H., A. O'Garra, M. Bigler, M. Rouleau, S. Antonenko, J.E. de Vries, and M.G. Roncarolo. 1997. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature. 389:737-742.
49. Ranges, G.E., I.S. Figari, T. Espevik, and M.A. Palladino, Jr. 1987. Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha. J. Exp. Med. 166:991-998.
50. Tada, T., S. Ohzeki, K. Utsumi, H. Takiuchi, M. Muramatsu, X.F. Li, J. Shimizu, H. Fujiwara, and T. Hamaoka. 1991. Transforming growth factor-beta-induced inhibition of T cell function. Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state. J. Immunol. 146:1077-1082.
51. Vanky, F., N. Nagy, C. Hising, K. Sjovall, B. Larson, and E. Klein. 1997. Human ex vivo carcinoma cells produce transforming growth factor beta and thereby can inhibit lymphocyte functions in vitro. Cancer Immunol. Immunother. 43:317-323.
52. Kadin, M.E., B.A. Agnarsson, L.R. Ellingsworth, and S.R. Newcom. 1990. Immunohistochemical evidence of a role for transforming growth factor beta in the pathogenesis of nodular sclerosing Hodgkin's disease. Am. J. Pathol. 136:1209-1214.
53. Newcom, S.R., K.K. Tagra, and M.E. Kadin. 1992. Neutralizing antibodies against transforming growth factor beta potentiate the proliferation of Ki-1 positive lymphoma cells. Further evidence for negative autocrine regulation by transforming growth factor beta. Am. J. Pathol. 140:709-718.
54. Xerri, L., E. Devilard, J. Hassoun, D. Olive, and F. Birg. 1997. In vivo expression of the CTLA4 inhibitory receptor in malignant and reactive cells from human lymphomas. J. Pathol 183:182-187.
55. Blair, P.L., J.L. Riley, B.L. Levine, K.P. Lee, N. Craighead, T. Francomano, S.J. Perfetto, G.S. Gray, B.M. Carreno, and C.H. June. 1998. CTLA-4 ligation delivers a unique signal to resting human CD4 T cells that inhibits interleukin-2 secretion but allows Bcl-XL induction. J. Immunol. 160:12-15.
56. Gribben, J.G., G.J. Freeman, V.A. Boussiotis, P. Rennert, C.L. Jellis, E. Greenfield, M. Barber, V.A. Restivo, Jr., X. Ke, G.S. Gray, et al. 1995. CTLA4 mediates antigen-specific apoptosis of human T cells. Proc. Natl. Acad. Sci. USA. 92:811-815.
57. Hollsberg, P., C. Scholz, D.E. Anderson, E.A. Greenfield, V.K. Kuchroo, G.J. Freeman, and D.A. Hafler. 1997. Expression of a hypoglycosylated form of CD86 (B7-2) on human T cells with altered binding properties to CD28 and CTLA-4. J. Immunol. 159:4799-4805.
58. Krummel, M.F., and J.P. Allison. 1995. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182:459-465.
59. Krummel, M.F., and J.P. Allison. 1996. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J. Exp. Med. 183:2533-2540.
60. Akbar, A.N., N. Borthwick, M, Salmon, W. Gombert, M. Bofill, N. Shamsadeen, D. Pilling, S. Pett, J.E. Grundy, and G. Janossy. 1993. The significance of low bcl-2 expression by CD45RO T cells in normal individuals and patients with acute viral infections. The role of apoptosis in T cell memory. J. Exp. Med. 178:427-438.
61. Estaquier, J., M. Tanaka, T. Suda, S. Nagata, P. Golstein, and J.C. Ameisen. 1996. Fas-mediated apoptosis of CD4+ and CD8+ T cells from human immunodeficiency virus-infected persons: differential in vitro preventive effect of cytokines and protease antagonists. Blood. 87:4959-4966.
62. Groux, H., D. Monte, B. Plouvier, A. Capron, and J.C. Ameisen. 1993. CD3-mediated apoptosis of human medullary thymocytes and activated peripheral T cells: respective roles of interleukin-1, interleukin-2, interferon-gamma and accessory cells. Eur. J. Immunol. 23:1623-1629.
63. Frisch, S.M., and H. Francis. 1994. Disruption of epithelial cell-matrix interactions induces apoptosis. J. Cell Biol. 124:619-626.
64. Guadagno, T.M., M. Ohtsubo, J.M. Roberts, and R.K. Assoian. 1993. A link between cyclin A expression and adhesion-dependent cell cycle progression. Science. 262:1572-1575.
65. Nunez, G., L. London, D. Hockenbery, M. Alexander, J.P. McKearn, and S.J. Korsmeyer. 1990. Deregulated Bcl-2 gene expression selectively pro-longs survival of growth factor-deprived hemopoietic cell lines. J. Immunol. 144:3602-3610.
66. Deckwerth, T.L., J.L. Elliott, C.M. Knudson, E.M. Johnson, Jr., W.D. Snider, and S.J. Korsmeyer. 1996. BAX is required for neuronal death after trophic factor deprivation and during development. Neuron. 17:401-411.
67. Hargreaves, R.G., N.J. Borthwick, M.S. Montani, E. Piccolella, P. Carmichael, R.I. Lechler, A.N. Akbar, and G. Lombardi. 1997. Dissociation of T cell anergy from apoptosis by blockade of Fas/Apo-1 (CD95) signaling. J. Immunol. 158:3099-3107.
68. Perez, V.L., L. Van Parijs, A. Biuckians, X.X. Zheng, T.B. Strom, and A.K. Abbas. 1997. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity. 6:411-417.
69. Boussiotis, V.A., B.J. Lee, G.J. Freeman, J.G. Gribben, and L.M. Nadler. 1997. Induction of T cell clonal anergy results in resistance, whereas CD28-mediated costimulation primes for susceptibility to Fas-and Bax-mediated programmed cell death. J. Immunol. 159:3156-3167.
70. Broome, H.E., C.M. Dargan, S. Krajewski, and J.C. Reed. 1995. Expression of Bcl-2, Bcl-x, and Bax after T cell activation and IL-2 withdrawal. J. Immunol. 155:2311-2317.
71. Behrens, T.W., and D.L. Mueller. 1997. Bcl-x and the regulation of survival in the immune system. Immunol. Res. 16:149-160.